Key result
Targeting RBM20 to modify titin isoforms shows promise for improving myocardial compliance in HFpEF.
Why the study?
Functional deficiency of the titin splicing factor RBM20 improves cardiac compliance and function in mice, indicating it may serve as a therapeutic target to reduce myocardial stiffness in HFpEF.
RBM20 inhibition represents a potential therapeutic strategy to improve myocardial compliance and alleviate diastolic dysfunction in HFpEF by modulating titin isoform switching.
several pathways. RNA binding motif protein 20 (RBM20) is a well-studied splicing factor of titin, functional deficiency of RBM20 in mice profile improved cardiac compliance and function, which indicated that RBM20 functions as a potential therapeutic target for mitigating myocardial stiffness by modulating titin isoforms. This minor review summarized how RBM20 and other splicing factors modify the titin isoforms ratio, therefore providing a promising target for improving the myocardial compliance of HFpEF.
No takes yet. Share an insight, caveat, or question.
Li et al. (2022) conducted a review in Heart Failure with Preserved Ejection Fraction (HFpEF). RBM20 targeting was evaluated. Targeting RBM20 and other splicing factors to modify the titin isoforms ratio provides a promising therapeutic strategy for improving myocardial compliance in HFpEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: